Evidence map›Paper›PMID 36553544›Full record

ArticleGenes2022

Optimal microRNA Sequencing Depth to Predict Cancer Patient Survival with Random Forest and Cox Models.

Rémy Jardillier, Dzenis Koca, Florent Chatelain, Laurent Guyon

Abstract read
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. DLD is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients.Apoptosis : an international journal on programmed cell death · 2024
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rémy JardillierUniv. Grenoble Alpes, CEA, Inserm, IRIG, BioSanté U1292, BCI, 38000 Grenoble, France.
Dzenis KocaUniv. Grenoble Alpes, CEA, Inserm, IRIG, BioSanté U1292, BCI, 38000 Grenoble, France.
Florent ChatelainUniv. Grenoble Alpes, CNRS, Grenoble INP, GIPSA-Lab, Institute of Engineering University Grenoble Alpes, 38000 Grenoble, France.
Laurent GuyonUniv. Grenoble Alpes, CEA, Inserm, IRIG, BioSanté U1292, BCI, 38000 Grenoble, France.ORCID 0000-0002-7674-2348

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: tumor profiling enables patient survival prediction. The two essential parameters to be calibrated when designing a study based on tumor profiles from a cohort are the sequencing depth of RNA-seq technology and the number of patients. This calibration is carried out under cost constraints, and a compromise has to be found. In the context of survival data, the goal of this work is to benchmark the impact of the number of patients and of the sequencing depth of miRNA-seq and mRNA-seq on the predictive capabilities for both the Cox model with elastic net penalty and random survival forest. (2) Results: we first show that the Cox model and random survival forest provide comparable prediction capabilities, with significant differences for some cancers. Second, we demonstrate that miRNA and/or mRNA data improve prediction over clinical data alone. mRNA-seq data leads to slightly better prediction than miRNA-seq, with the notable exception of lung adenocarcinoma for which the tumor miRNA profile shows higher predictive power. Third, we demonstrate that the sequencing depth of RNA-seq data can be reduced for most of the investigated cancers without degrading the prediction abilities, allowing the creation of independent validation sets at a lower cost. Finally, we show that the number of patients in the training dataset can be reduced for the Cox model and random survival forest, allowing the use of different models on different patient subgroups.

Indexed as

Lung NeoplasmsMicroRNAsGene Expression ProfilingHumansProportional Hazards ModelsRandom ForestRNA, MessengerMicroRNAsRNA, MessengercancerCox modelmicroRNArandom survival forest modelsequencing depthsurvival

Identifiers

PMID36553544
PMCPMC9777708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.